VANCOUVER, British Columbia, April 30, 2024 Zymeworks Inc. , a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the.
NEW YORK, April 28, 2024 /PRNewswire/ Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. . Such investors are advised to contact Danielle Peyton at.
NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME). Such investors are advised
NEW YORK, April 20, 2024 /PRNewswire/ Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. . Such investors are advised to contact Danielle Peyton at.
/PRNewswire/ Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. ("Zymeworks" or the "Company") (NASDAQ: ZYME). Such investors.